In this study, we demonstrated that the combination of RocA and anti-PD-1 antibody exerted potent antitumor activity even on the immune-cold B16F10 melanoma, a type of tumor with poor response to ICB therapy. The gene discussed is PDCD1; the disease is melanoma.